Updated BPX-501 results at ASH 2016

Now Enrolling

We are developing novel stem cell transplant, TCR and CAR T cell therapies. Our product candidates incorporate molecular switches designed to allow activation or elimination of therapeutic cells once inside the body. We believe cellular control holds the key to safer, more effective cell therapies.READ MORE

105 patients treated with BPX-501 in BP-004 trial; 85 with more than 100 days of follow-up Company reports encouraging results with BPX-501 in high-risk pediatric leukemia patients SAN DIEGO--(BUSINES ... READ MORE

Lead product candidate BPX-501 is an adjunct T-cell therapy being evaluated in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant (HSCT), with encouraging results. BPX-501, with the CaspaCIDe® safety switch, has the potential to expand eligibility for a curative stem cell transplant to the 70% of patients who lack a matched donor. Bellicum is also launching clinical trials of its BPX-601 GoCAR-T therapy in pancreatic cancer and BPX-701 TCR therapy in acute myeloid leukemia and myelodysplastic syndromes. LEARN MORE